{"id":991657,"date":"2026-08-06T18:24:03","date_gmt":"2026-08-06T22:24:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/agomab-reports-half-year-2026-financial-results-and-confirms-2026-outlook\/"},"modified":"2026-08-06T18:24:03","modified_gmt":"2026-08-06T22:24:03","slug":"agomab-reports-half-year-2026-financial-results-and-confirms-2026-outlook","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/agomab-reports-half-year-2026-financial-results-and-confirms-2026-outlook\/","title":{"rendered":"Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook"},"content":{"rendered":"
\n

— Regulatory alignment with U.S. Food and Drug Administration (FDA) on key elements of NOV-ERA Phase 2b study design with Ontunisertib in Fibrostenosing Crohn\u2019s Disease (FSCD), including Novel Primary Endpoint of Endoscopic Passability —<\/p>\n

— Topline Data from Open-Label Long-term Extension Study (OLE) Part\u00a0of STENOVA Study with Ontunisertib in FSCD and from Phase 1b Idiopathic Pulmonary Fibrosis (IPF) Study Cohort with AGMB-447 Expected in Coming Months\u00a0—<\/p>\n

— On Track to Initiate NOV-ERA Phase 2b Study in FSCD with Ontunisertib and Phase 2 Study in with AGMB-447 in IPF in Second Half of 2026\u00a0—<\/p>\n

— Cash and Cash Investments at June 30, 2026 of \u20ac252 Million, including $208 Million in Gross Proceeds from Initial Public Offering (IPO), Expected to Support Cash Runway into First Half of 2029 —<\/p>\n

\n Antwerp, Belgium, August 6, 2026<\/b>\u00a0\u2013 Agomab Therapeutics NV<\/a> (Nasdaq: AGMB) (\u201cAgomab\u201d), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today reported financial results for the half\u00a0year period ended June\u00a030, 2026, and confirmed its outlook for the second half of 2026.<\/p>\n

\u201cIn the first half of 2026, we continued to execute on our clinical and operational strategy, and we are on track with the clinical read-outs and trial initiations of ontunisertib and AGMB-447 expected later this\u00a0year,\u201d said\u00a0Tim Knotnerus, Chief Executive Officer of Agomab. \u201cOur recent engagement with the FDA provides important support for our development strategy with ontunisertib, and we believe the NOV-ERA Phase 2b study will be a crucial next step in evaluating ontunisertib\u2019s potential as a differentiated therapy to address the high unmet medical need in FSCD. As we head into a catalyst-rich second half of 2026, we especially look forward to the OLE results with ontunisertib and first IPF data with AGMB-447.\u201d<\/p>\n

Pierre Kemula, Chief Financial Officer of Agomab, added, \u201cThe first half of 2026 marked a defining moment for Agomab, with our Nasdaq IPO raising $208 million in gross proceeds, extending the cash runway into the first half of 2029. We are well-resourced to drive our clinical programs forward with both focus and discipline. As we look ahead to important milestones across our fibro-inflammatory disease portfolio, we are well positioned to deliver meaningful value for patients and shareholders alike.\u201d<\/p>\n

\n First Half 2026 Program Highlights and Anticipated Milestones<\/b>\n <\/p>\n